PRIMARY STUDY

Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease

Key Findings:  This study demonstrates that the non-psychotropic cannabinoid cannabigerol (CBG) attenuates experimental colitis in mice by reducing inflammatory markers, nitric oxide production, and oxidative stress through CB2-modulated mechanisms, highlighting its potential as a therapeutic candidate for inflammatory bowel disease.